Mereo BioPharma Group plc

Mereo BioPharma is an innovative leader in the biopharma sector with a focus on developing and optimizing the value of novel medicines acquired from large pharmaceutical companies designed to address significant unmet medical needs in rare and specialty disease areas. Mereo has built an initial mid-late stage portfolio of four exceptionally well characterised novel products, three from Novartis and one from AstraZeneca, for the treatment of diseases with considerable unmet medical need.

Company Type
Keywords
Donald Coppen
LinkedIn logo Director of Corporate Development 
John Richard
LinkedIn logo Head of Corporate Development